The quality of guidelines in non-pharmacological prevention and management of chemotherapy-induced neuropathy: A review.

Shahin Salarvand,Fariba Taleghani,Simin Hemati,Payman Adibi

doi:10.4081/oncol.2018.359

Abstract

Chemotherapy-induced peripheral neuropathy is a common adverse effect occurring in patients undergoing neurotoxic chemotherapy. However, there is no FDA-approved treatment option for it. Given the importance of clinical practice guidelines in this area, this study aimed to determine the methodological quality of extant CIPN guidelines. The study was done as part of the adaptation process of CIPN related CPGs at Isfahan University of Medical Sciences, Iran. A systematic search of published CPGs about chemotherapy-induced CIPN in which the AGREE II instrument was applied for appraising CPGs of CIPN was performed. In general, amongst all of the AGREE II Instrument’s domains in the evaluated CPGs, the clarity of presentation and stakeholder involvement domains took favorable scores; and other domains obtained unfavorable and relatively favorable scores. The quality of cancer therapy-induced neuropathy CPGs needs to be improved and designing high-quality CPGs must be considered.

Highlights

Chemotherapy-induced peripheral neuropathy is a commonWorldwide, the numbers of cancer survivors have increased adverse effect occurring in patients undergoing neurotoxic significantly
The study was done as part of the adaptation process of chemotherapy-induced peripheral neuropathy (CIPN) related Clinical practice guidelines (CPGs) in Isfahan University of Medical Sciences, Iran
The AGREE II Instrument comprises six tains 6 domains and subcategories as 23 items.[6] ly Selection criteria Inclusion criteria: i) The CPG has been presented as a guiden line; ii) adults aged ≥18 years old are the target population; iii) o neuropathy has been induced by cancer therapy; iv) the guideline is in the English language; v) the CPG had recommendations about e CIPN; vi) related institutions, communities, societies, associations, s cancer care groups which developed the CPG were mentioned. u Exclusion criteria: systematic reviews, clinical pathways, prol tocols, editorial, instructional booklets, patients’ guides, books, ia and narrative reviews were excluded. c Search strategy r We conducted a systematic search for finding the guidelines of e the databases and sites as follows: NCCN

Summary

Introduction

Chemotherapy-induced peripheral neuropathy is a commonWorldwide, the numbers of cancer survivors have increased adverse effect occurring in patients undergoing neurotoxic significantly. Given the importance of clinical practice guidelines ly in this area, this study aimed to determine the methodological n quality of extant CIPN guidelines. The study was done as part of o the adaptation process of CIPN related CPGs at Isfahan University of Medical Sciences, Iran. A systematic search of published CPGs e about chemotherapy-induced CIPN in which the AGREE II instrus ment was applied for appraising CPGs of CIPN was performed. Amongst all of the AGREE II Instrument’s domains in the l evaluated CPGs, the clarity of presentation and stakeholder ia involvement domains took favorable scores; and other domains obtained unfavorable and relatively favorable scores. The quality rc of cancer therapy-induced neuropathy CPGs needs to be improved and designing high-quality CPGs must be considered

Objectives

Methods

Discussion

Conclusion